Loading...
•
Sep 30, 2020
Pliant Therapeutics Q3 2020 Earnings Report
Pliant Therapeutics reported financial results for the third quarter of 2020 and provided a corporate update.
Key Takeaways
Pliant Therapeutics reported related party revenue of $4.8 million for the third quarter of 2020, compared to none for the prior-year quarter. Research and development expenses were $16.9 million, and net loss was $16.5 million. The company had cash, cash equivalents, and short-term investments of $294.0 million as of September 30, 2020.
Enrollment of PLN-74809 Phase 2a 12-week trials in IPF and PSC progressing.
Phase 2a PET imaging trial of PLN-74809 in IPF is enrolling.
Completed dosing of an extended Phase 1 dose escalation trial of PLN-74809 in healthy volunteers.
Phase 2a trial of PLN-74809 treatment of COVID-19 related ARDS has been initiated.
Pliant Therapeutics
Pliant Therapeutics
Forward Guidance
Pliant believes it has sufficient funds to meet its operating and capital requirements into 2023.